Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01925131 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)

Study Title
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia (NCT01925131)

Trial Description
This phase I trial studies the side effects and best dose of inotuzumab ozogamicin (also known as CMC-544) when given together with combination chemotherapy in treating patients with relapsed or refractory acute leukemia. Immunotoxins, such as inotuzumab ozogamicin, can find cancer cells that express cluster of differentiation (CD)22 and kill them without harming normal cells.

Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving inotuzumab ozogamicin together with combination chemotherapy may kill more cancer cells.

This trial is sponsored by Southwestern Oncology GroupNational Cancer Institute (NCI). [1]

Study Data

  • Condition: Leukemia
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 38
  • Start: April 2014
  • Estimated Completion: February 2019
  • Last verified: March 2015

Study Schematic 

NCT01925131 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)

Click here to Return to Drug map


Last Editorial review: July 31, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar